USPTO serial 79434747
ASTRID
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- VAGHANI, MAYUR C
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 686 means your mark is published in the USPTO Official Gazette and in the 30-day opposition period. If no opposition is filed, prosecution typically continues toward registration or a Notice of Allowance. Monitor the opposition window. After it closes, watch for Notice of Allowance (intent-to-use) or registration (use-based).
Need help with ASTRID?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ashley M. Robinson
Ashley M. Robinson Bradley Arant Boult Cummings LLP1819 Fifth Avenue NorthBirmingham, AL 35203United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Diagnostic preparations for medical purposes; diagnostic preparations and materials in the nature of diagnostic reagents, diagnostic antibody reagents or antibodies, monoclonal antibodies and buffer solutions for use in in vitro diagnostics, reagents for use in in vitro diagnostics, and medical diagnostic test strips for blood analysis, all for medical and veterinary purposes; chemical, biochemical and biological preparations, namely, chemical reagents for medical purposes, biochemical reagents for medical purposes; chemical and biochemical preparations, namely, diagnostic reagents, diagnostic antibody reagents or antibodies, monoclonal antibodies and buffer solutions for use in in vitro diagnostics, and reagents for use in in vitro diagnostics, all for veterinary purposes; biological preparations, namely, diagnostic reagents, diagnostic antibody reagents or antibodies, monoclonal antibodies and buffer solutions for use in in vitro diagnostics, and reagents for use in in vitro diagnostics, all for veterinary purposes; clinical diagnostic reagents for medical use; medical diagnostic reagents and assays for testing of body fluids; diagnostic biomarker reagents for medical or veterinary purposes; diagnostic preparations for medical purposes used by medical laboratories; medical diagnostic test strips for blood analysis; diagnostic test kits consisting primarily of diagnostic reagents, antibody reagents or antibodies, buffers, and reagents, for use in in vitro diagnostics, and test strips for blood analysis for disease testing; in vitro diagnostic agents for medical use; in-vitro diagnostics for veterinary purposes; diagnostic test kits for medical purposes consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents, for use in in vitro diagnostics, and test strips for blood analysis disease testing; diagnostic test kits for veterinary purposes consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for blood analysis for disease testing; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for blood analysis for disease testing for medical purposes; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for blood analysis for disease testing for veterinary purposes; medical diagnostic test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for detecting acute aortic syndrome; diagnostic test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for detecting aortic dissection; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostic apparatus, and test strips for detecting acute aortic syndrome; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents, antibodies, buffers, and reagents for use in in vitro diagnostics, and test strips for detecting aortic dissection; diagnostic test kits consisting primarily of diagnostic reagents, antibody reagents or antibodies, monoclonal antibodies, buffer solutions, reagents and test strips for blood analysis, all for use in in vitro diagnostics for diagnosing the recurrence or progression of disease in patients following surgery; diagnostic test kits consisting primarily of diagnostic reagents, antibody reagents or antibodies, monoclonal antibodies, buffer solutions, reagents and test strips for blood analysis, all for use in in vitro diagnostics for diagnosing the recurrence or progression of cardiovascular disease in patients following cardiological interventions; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents or antibodies, monoclonal antibodies, buffer solutions, reagents, and test strips for blood analysis, all for use in in vitro diagnostics for diagnosing the recurrence or progression of disease in patients following surgery; diagnostic rapid test kits consisting primarily of diagnostic reagents, antibody reagents or antibodies, monoclonal antibodies, buffer solutions, reagents and test strips for blood analysis, all for use in in vitro diagnostics for diagnosing the recurrence or progression of cardiovascular disease in patients following cardiological interventions and surgery. | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Sep 29, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 29, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 23, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 1, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 7, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 7, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 7, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 5, 2026 | RFNT | REFUSAL PROCESSED BY IB | — |
| Feb 18, 2026 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Feb 18, 2026 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jan 24, 2026 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jan 23, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 21, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 16, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Oct 16, 2025 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Oct 16, 2025 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |